Drug Profile
HCP 1305
Alternative Names: HCP1305Latest Information Update: 05 Sep 2018
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihypertensives; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperlipidaemia; Hypertension
Most Recent Events
- 05 Sep 2018 Discontinued - Phase-III for Hyperlipidaemia in South Korea (unspecified route)
- 05 Sep 2018 Discontinued - Phase-III for Hypertension in South Korea (unspecified route)
- 01 May 2015 Hanmi Pharmaceuticals completes a phase I trial in Healthy volunteers (Combination therapy) in South Korea (NCT04039724)